H6Z0 Stock Overview
A biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
LakeShore Biopharma Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.04 |
| 52 Week High | US$10.30 |
| 52 Week Low | US$0.49 |
| Beta | 0.74 |
| 11 Month Change | -4.45% |
| 3 Month Change | -43.02% |
| 1 Year Change | -62.57% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| H6Z0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.0% | -0.7% | -0.02% |
| 1Y | -62.6% | -17.2% | 8.2% |
Return vs Industry: H6Z0 underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: H6Z0 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| H6Z0 volatility | |
|---|---|
| H6Z0 Average Weekly Movement | 29.3% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: H6Z0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: H6Z0's weekly volatility has increased from 20% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 758 | Wang Xu | www.ysbiopharm.com |
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company’s product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines.
LakeShore Biopharma Co., Ltd Fundamentals Summary
| H6Z0 fundamental statistics | |
|---|---|
| Market cap | €47.09m |
| Earnings (TTM) | -€57.45m |
| Revenue (TTM) | €76.00m |
0.6x
P/S Ratio-0.8x
P/E RatioIs H6Z0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H6Z0 income statement (TTM) | |
|---|---|
| Revenue | CN¥573.42m |
| Cost of Revenue | CN¥187.36m |
| Gross Profit | CN¥386.06m |
| Other Expenses | CN¥819.52m |
| Earnings | -CN¥433.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -22.72 |
| Gross Margin | 67.33% |
| Net Profit Margin | -75.59% |
| Debt/Equity Ratio | 71.3% |
How did H6Z0 perform over the long term?
See historical performance and comparison